Nevirapine (NVP) is a simple, effective and relatively safe antiretroviral drug now widely used in low resource settings around the world to prevent mother-to-child transmission of HIV. NVP is also a useful drug to use as part of treatment regimens. Concern has been raised that exposure to this drug for prevention may compromise its use in treatment. The concern has arisen because viral mutations which confer resistance to NVP appear to be common among HIV-infected women and children after exposure to even single dose NVP. A study is proposed to test whether or not exposure to NVP for prevention of mother-to-child HIV transmission, and the resulting NVP resistance mutations associated with its use, will adversely influence response to a subsequent treatment regimen which includes NVP. The study will recruit HIV-infected women and their children, NVP-exposed and unexposed, in Johannesburg, South Africa, who meet criteria for starting antiretroviral treatment and will start them on a treatment regimen which includes NVP. HIVinfected women and children exposed to NVP prophylaxis will be compared to similar unexposed women and children. Further, among those exposed to NVP prophylaxis, those with NVP resistance mutations at 6 weeks post-NVP exposure will be compared to those exposed to NVP but who do not have detectable mutations. The primary study outcome is treatment failure defined on the basis of virologic outcomes at 6 months after starting treatment. Secondary objectives of the study are to characterize the nature of viral resistance mutations associated with NVP prophylaxis (including the specific mutations present, their occurrence in plasma and/or PBMCs, their frequency if the threshold of detection is lowered to detect mutations present at low frequencies in the viral population) and to investigate whether these characteristics of viral resistance explain treatment failure. The study will generate empirical data essential for formulation of evidence-based treatment policies for the hundreds of thousands of HIV-infected women and children living in low resource settings who are likely to have had prior exposure to NVP. ? ?

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD047177-03
Application #
7062143
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Ryan, Kevin W
Project Start
2004-09-01
Project End
2009-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
3
Fiscal Year
2006
Total Cost
$496,670
Indirect Cost
Name
Columbia University (N.Y.)
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Shiau, Stephanie; Strehlau, Renate; Shen, Jing et al. (2018) Biomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr 78:549-556
Shiau, Stephanie; Strehlau, Renate; Technau, Karl-Günter et al. (2017) Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants. AIDS 31:355-364
Moholisa, Retsilisitsoe R; Schomaker, Michael; Kuhn, Louise et al. (2016) Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. Pediatr Infect Dis J 35:e378-e383
Giandhari, Jennifer; Basson, Adriaan E; Sutherland, Katherine et al. (2016) Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. Antimicrob Agents Chemother 60:2248-56
Giandhari, Jennifer; Basson, Adriaan E; Coovadia, Ashraf et al. (2015) Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Res Hum Retroviruses 31:776-82
Kuhn, Louise; Schramm, Diana B; Shiau, Stephanie et al. (2015) Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed. AIDS 29:1053-60
Moholisa, Retsilisitsoe R; Schomaker, Michael; Kuhn, Louise et al. (2014) Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther 19:399-406
Shiau, Stephanie; Kuhn, Louise; Strehlau, Renate et al. (2014) Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. BMC Pediatr 14:39
Hunt, Gillian M; Morris, Lynn; Moorthy, Anitha et al. (2014) Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Virol Methods 207:182-7
Kuhn, Louise; Hunt, Gillian; Technau, Karl-Günter et al. (2014) Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS 28:1673-8

Showing the most recent 10 out of 28 publications